SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.

Jeffrey L Bennett,Kazuo Fujihara,Ho Jin Kim,Romain Marignier,Kevin C O'Connor,Robert C Sergott,Anthony Traboulsee,Heinz Wiendl,Jens Wuerfel,Scott S Zamvil,Veronica G Anania,Regine Buffels, Thomas Künzel,Annemarie N Lekkerkerker,Siân Lennon-Chrimes,Sean J Pittock

Frontiers in neurology（2023）

引用 0|浏览34

暂无评分

摘要

SAkuraBONSAI will incorporate comprehensive imaging, fluid biomarker, and clinical assessments in patients with AQP4-IgG+ NMOSD. SAkuraBONSAI will provide new insights into the mechanism of action of satralizumab in NMOSD, while offering the opportunity to identify clinically relevant neurological, immunological, and imaging markers.

查看译文

关键词

biomarkers,magnetic resonance imaging (MRI),neuromyelitis optica spectrum disorder (NMOSD),optical coherence tomography (OCT),relapse,satralizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要